Japanese Biotech Stock News

TSE:8604
TSE:8604Capital Markets

Assessing Nomura’s Value After Share Price Surge and Bank of Japan Rate Hike in 2025

If you are wondering whether to stick with Nomura Holdings or add it to your watchlist, you are not alone. Investors all over the globe are sizing up what is turning out to be one of Japan’s most interesting financial stories this year. The stock may have dropped 6.6% over the past week, but do not let short-term noise drown out the bigger narrative. Nomura is up a massive 42.1% over the last 12 months and an eye-watering 166.5% over the past five years. That is not just a recovery, but a...
TSE:2201
TSE:2201Food

Evaluating Morinaga After Recent Stock Slide and Industry Shifts in 2025

Trying to figure out whether Morinaga&Co is a good buy right now? You are definitely not alone. With so many moving parts in today's markets, it's easy to get caught up in short-term dips and surges. Morinaga&Co’s stock has slid by 3.8% in the last week and is down 4.9% over the past month. Year to date, shares are off 5.2%, adding up to a 7.3% dip over the last twelve months. However, if you take a step back, there is an interesting twist: over the last 3 and 5 years, the stock posted...
TSE:2830
TSE:2830Food

Aohata (TSE:2830) Profit Recovery Challenges Bearish Narratives, But Valuation Premium Raises Concerns

Aohata (TSE:2830) posted a net profit margin of 1.3%, a slight uptick from last year’s 1.2%, with EPS reflecting a notable 13.5% earnings growth over the past year. This marks a stark contrast to the company’s five-year average earnings decline of 24.4% per year. Despite this sharp turnaround, shares trade at an elevated ¥3,695, resulting in a lofty 110.2x Price-To-Earnings Ratio. This is far above the peer and industry averages, raising questions about valuation sustainability in light of...